%0 Journal Article
%T Emerging therapies in hereditary ataxias.
%A Eisel MLS
%A Burns M
%A Ashizawa T
%A Byrne B
%A Corti M
%A Subramony SH
%J Trends Mol Med
%V 0
%N 0
%D 2024 Aug 16
%M 39153956
%F 15.272
%R 10.1016/j.molmed.2024.07.008
%X Recent investigations have defined the pathophysiological basis of many hereditary ataxias (HAs), including loss-of-function as well as gain-of-function mechanisms at either the RNA or protein level. Preclinical studies have assessed gene editing, gene and protein replacement, gene enhancement, and gene knockdown strategies. Methodologies include viral vector delivery of genes, oligonucleotide therapies, cell-penetrating peptides, synthetic transcription factors, and technologies to deliver therapies to defined targets. In this review, we focus on Friedreich ataxia (FRDA) and the polyglutamine ataxias in which translational research is active. However, much remains to be done to identify safe and effective molecules, create ideal delivery methods, and perform innovative clinical trials to prove the safety and efficacy of treatments for these rare but devastating diseases.